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Goal. To study the eﬀect of combination antiviral therapy with tenofovir and emtricitabine or lamivudine with and without prior
monotherapywithlamivudine.Study. Wereviewed charts of31 HIV-/HBV-coinfectedpatients. Twelve 3TC-na¨ ıvepatients initially
received tenofovir plus emtricitabine. Nineteen epivir experienced patients who had previously failed epivir were given tenofovir
plusemtricitabine.Results. BaselinemedianHBVDNA wassimilarinthe epivir-na¨ ıve(5.8×107 copies/mL)andexperienced group
(7.3×107 copies/mL, P = .65). The median time to complete suppression of HBV was 466 days in the na¨ ıve group and 877 days
in the experienced (P = .001). After 12 months, 6/10 (60%) na¨ ıve patients and 3/14 (21%) experienced patients had HBV DNA
below the detectionlimit (P = .067). After 24 months, 5/5 (100%) na¨ ıve patients and 4/13 (31%) experienced patients had an
undetectable HBV DNA level (P = .015). Conclusions. The median time to suppression of HBV DNA was signiﬁcantly shorter
among treatment na¨ ıve patients. There was a signiﬁcantly greater proportion of na¨ ıve patients with suppressed HBV DNA at 24
months.Our results support using initial dual therapy in those with HIV/HBV coinfection.
1.Introduction
There are an estimated 400 million people worldwide with
chronic hepatitis B virus (HBV) infection [1]a n da n
estimated 36 million people infected with human immun-
odeﬁciency virus (HIV) [2]. Due to similar modes of
transmission, it is not surprising that coinfection with HBV
is common, with estimates of the prevalence of coinfection
varying from 4 to 23% [3–11]. In those areas where
antiretroviral treatment has succeeded in reducing mortality
from acquired immune deﬁciency syndrome (AIDS) and
its associated opportunistic infections, the proportion of
mortality due to hepatic disease has increased [12–16].
There is no conclusive evidence that coinfection with
HBV adversely aﬀects the outcome of HIV treatment.
Neither the number of AIDS-deﬁning events nor the CD4+
cellresponse toantiretroviral treatment wasaﬀectedbybeing
HBV surface antigen positive (HBsAg+) in the EuroSIDA
cohort of 9082 HIV infected patients where 8.7% were
HBsAg+ [5]. A similar lack of eﬀect was seen in a cohort
of 3180 Danish HIV patients, 6% of whom were HBsAg+
[7], as well as in smaller cohorts in Italy [17], South Africa
[18], and Taiwan [9]. The consistency of the data suggests
thatthislackofeﬀectofHBVcoinfectiononresponse toART
is independent of demographic factors.
In contrast, HIV coinfection appears to have a negative
eﬀect on the course of chronic HBV infection. HIV coin-
fection is associated with increased HBV replication and
levels of HBV viremia and with impaired immune responses
to HBV [19–21]. Patients with coinfection have increased
rates of ﬁbrosis [22] and accelerated progression to cirrhosis
and hepaticfailure, with consequentincreases inliver-related
mortality [5, 23, 24]. Antiretroviral therapy has been shown
to improve outcomes for those with HBV monoinfection
[25], and it may reasonably be expected to reduce long-
term liver-related mortality in HIV-coinfected patients as
well [26, 27]. As a result, the IAS-USA and DHHS both
recommend that antiretroviral therapy be oﬀered to those
with active HBV infection regardless of CD4 T-cell count
[28–30].2 ISRN Gastroenterology
Among those with HBV monoinfection, therapy with
lamivudine (3TC)has proventobeeﬀectiveinbothreducing
HBV viremia and in reducing rates of progression to
cirrhosis and hepatocellular carcinoma compared to placebo
[25]. However, HBV resistance to 3TC develops relatively
quickly. After four years of therapy, up towards 70% of
patientstreatedwith3TCaloneforHBVmonoinfection have
developed resistance [31, 32]. Resistance may develop even
more rapidly in those with HIV/HBV coinfection. Only 47%
of patients receiving 3TC had HBV DNA levels less than
2.5pg/mL after two years [33], and after 4 years as many
as 94% may have mutations conferring resistance to 3TC
[34]. Persons with HIV/HBV coinfection readily accumulate
multiple mutations conferring resistance to 3TC [35]a n d
appear to do so more frequently than those with HBV
infection alone [36].
Due to the high risk of selecting resistant HBV, ART
regimens containing 3TC as the sole agent with activity
against HBV are now considered suboptimal for those with
HIV/HBVcoinfection. ARTregimens containing two reverse
transcriptase inhibitors active against HBV (i.e., tenofovir
(TDF) combined with either 3TC or emtricitabine (FTC))
are therefore currentlyrecommended as ﬁrst-line therapy for
coinfected patients [3, 21, 29, 37, 38].
Despite this recommendation, there are limited data
demonstrating the superiority of combination therapy using
two agents with activity against HBV. For example, a
randomized clinicaltrial comparing 3TC,TDF,and thecom-
bination of TDF/3TC demonstrated the expected inferiority
of 3TC monotherapy to TDF/3TC. However, it failed to
show a signiﬁcant diﬀerencebetweenTDF monotherapy and
TDF/3TC [39].
In contrast, a cross-sectional study of three cohorts with
a combined total of 122 persons with HIV/HBV coinfection
showedthatthosereceivingtwoagents(TDFwitheither3TC
orFTC) were less likelyto have HBV DNAlevelsgreater than
20,000IU/mL than those receiving either TDF or 3TC/FTC
alone at the time of observation [40]. However, due to the
design of the study, it was not possible to examine the
treatment-induced changes between the diﬀerent treatment
groups. It is therefore not yet clear whether initial treat-
ment with combination therapy in HIV/HBV coinfection
improves outcomes compared to combination therapy after
failure of 3TC.
T h eg o a lo ft h ec u r r e n ts t u d yw a st oa n a l y z et h eH B V -
related virologic response to the combination of TDF and
FTCin 3TC-na¨ ıve patients with HIV/HBVcoinfection, com-
pared to 3TC-experienced patients who have experienced
treatment failure. We evaluated the frequency of complete
HBV DNA suppression after one- and two-years treatment
anddeterminedthetimefromstartingtreatmenttocomplete
suppression of measurable HBV DNA.
2.Materialsand Methods
2.1. Patients. We conducted a retrospective review of the
electronic medical records(EMR)ofpatientswith HIV/HBV
coinfection at the Bellevue Hospital Center (BHC) in New
York City during the period 01/01/2002 to 03/31/2008.
Inclusion criteria were documented HIV-/HBV-coinfection,
age >18 years, ≥2 measurements of quantitative HBV DNA,
detectable HBV DNA at baseline, and provision of care at
the BHC Virology Clinic. 31 of 159 HIV-/HBV-coinfected
patients met the inclusion criteria. Twelve patients who
had not previously received 3TC were given initial therapy
with TDF and FTC as part of their anti-HIV regimen (the
“3TC na¨ ıve” group). Thirty-two other patients were initially
started on a 3TC-based anti-HIV regimen. Of these 32, 19
failed to maintain a suppressed HBV viral load as evidenced
by detectable HBV DNA levels (the “3TC-experienced”
group) and therefore met our inclusion criteria. Eleven
had undetectable HBV DNA while receiving 3TC as the
only HBV-active agent but were changed to a regimen
of TDF/FTC, presumably due to concern for long-term
resistance. These patients were not included in our study.
Three had received 3TC in the past, but their regimen
was stopped before clinical or virologic failure could be
determined. These 3 patients were also excluded from the
analysis. Institutional Review Board approval was obtained
for this retrospective study.
2.2. Laboratory Testing. Study baseline (Day 0) was deﬁned
as the date that TDF and FTC were begun. Baseline lab
valuesincludedHBVserologies, HBVDNAPCR(viral load),
liver function tests, CD4+ cell count, and HIV-1 RNA PCR
(viral load). HBV surface antigen (HBsAg) and HBV surface
antibody (HBsAb) were determined on a Siemens Centaur
analyzer (chemiluminescence immunoassay protocol). HBV
DNA PCR was performed at the discretion of the provider
u s i n gt h eR o c h eC O B A Sa s s a y ;t h eB H Cl a b o r a t o r yr e p o r t e d
a linear range of 6IU/mL to 1.10 × 108 IU/mL. HBe antigen
(HBeAg) and antibody (HBeAb) testing was performed by
EIA at Quest Diagnostics (Teterboro, NJ, USA). HIV-1 RNA
PCR was performed using the Roche Amplicor test (lower
limit of detection 50 copies/mL). CD4+ lymphocyte counts
were performed at BHC using a Fluorescence Activated Cell
Sorter. ALT measurement was performed using a Siemens
Advia 2400 analyzer, with an upper limit of normal of
35IU/L.
2.3. Statistical Analysis. Time to undetectable viral load was
estimated by Kaplan-Meier analysis with the Log Rank test
used to estimate signiﬁcance. The time at risk was the time
from baseline to the last measurement of HBV DNA (for
censored observations) or until the ﬁrst undetectable level of
HBV DNA.
Statistical analyses were performed with SPSS for win-
dows (version 17.0: SPSS inc., Chicago, Ill, USA). The Chi-
square test was used to compare categorical variables. The
two sided t-test for equality of means was used for contin-
uous variables. P values of <.05 were deemed statistically
signiﬁcant, and those between.05 and.10 were deemed to
suggest a trend in the data.
3.Results
At baseline, the mean age and proportion of male patients
were similar amongst the 3TC-na¨ ıve and 3TC-experiencedISRN Gastroenterology 3
Table 1: Baseline characteristics of 3TC-na¨ ıve and experienced
groups.
3TC na¨ ıve
(n = 12)
3TC experienced
(n = 19)
Mean Age 46 45 P = .89
Male, % of
patients 83% 89% P = .54
Mean HBV DNA
level (IU/mL) 5.8 × 107 7.6 × 107 P = .60
Mean ALT
level (IU/L) 46 82 P = .10
Mean CD4
count
(cells/mm3)
155 333 P = .003
Mean HIV RNA
level (Copies/mL) 59,285 30,034 P = .17
HBeAg positive,
no. of pts (%) 7 (58%) 11 (69%) P = .728
HCV infection 1 0
Table 2: Patients with suppressed HBV VL 12 monthsafter starting
TDF/FTC.
Detectable Suppressed P = .067
3TC na¨ ıve
(n = 10)
4 (40%) 6 (60%) 10 (100%)
3TC
experienced
(n = 14)
11 (79%) 3 (21%) 14 (100%)
Total 15 9 24
patients (Table 1). The 3TC-experienced group had signiﬁ-
cantly higher CD4+ cell counts (155 versus 333, P = .003)
and nonsigniﬁcantly lower HIV viral loads than the 3TC-
na¨ ıve group at baseline (5.93 × 104 versus 3.00 × 104, P =
.17).
The 3TC-na¨ ıve group had a median HBV DNA of 5.8 ×
107 copies/mL compared with 7.3 × 107 copies/mL in the
3TC experienced (P = .60). Although the mean ALT in the
3TC-experienced group was higher than for the 3TC-na¨ ıve
group (82 versus 46IU/L), the diﬀerence between the groups
was not statistically signiﬁcant (P = .10).
The median time to complete suppression of HBV DNA
in the 3TC-na¨ ıve patients was 466 days, compared with 877
days in the 3TC-experienced group (P = .001) (Figure 1).
At the time of HBV DNA suppression or last recorded HBV
DNA level, there was no signiﬁcant diﬀerence between the
two groups in HIVRNAsuppression (8/12versus 13/19,P =
.92).
After12months, 6/10(60%)3TC-na¨ ıvepatientsbutonly
3/14 (21%) 3TC-experienced patients had an undetectable
HBV DNA (P = .092) (Table 2). After 24 months, 5/5
(100%) of 3TC-na¨ ıve patients but only 4/13 (31%) 3TC-
experienced patients had an undetectable HBV DNA (P =
.015) (Table 3). Among those who were initially HBeAg+,
loss of detectable HBeAg occurred in 1/7 (14%) 3TC-na¨ ıve
and 1/11 (9%) 3TC-experienced patients.
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Figure 1: Kaplan-Meier function of time to suppression.
Table 3: Patients with suppressed HBV VL 24 monthsafter starting
TDF/FTC.
Detectable Suppressed P = .015
3TC na¨ ıve
(n = 5)
0 (0%) 5 (100%) 5 (100%)
3TC
experienced
(n = 13)
9 (69%) 4 (31%) 13 (100%)
Total 99 1 8
4.Discussion
The present study shows that for persons coinfected with
HIV and HBV, initial treatment with a combination of
two agents that have activity against HBV resulted in a
signiﬁcantly shorter time to suppression of HBV DNA
level, as compared to using combination therapy after prior
monotherapy with 3TC. Our study supplements a prior
retrospective studywhich compared10personswho received
TDF + 3TC as part of their initial regimen with 20 3TC-
experienced persons who received TDF add-on; in that
study, a greater proportion of persons initially receiving
combination therapy achieved HBV DNA <2000 copies/mL
(80% versus 55%) at one year of followup, although the
result did not reach statistical signiﬁcance [41].
These observations are in contrast to those of two
other studies. In one retrospective study, 25 treatment-
na¨ ıve patients who received TDF + 3TC were compared
with 50 3TC-experienced patients who experienced HBV
virologic breakthrough and then had TDF added; of those
who initially received combination therapy, 76% achieved
HBV DNA levels <1000 copies/mL, compared with 84%
who had TDF added after 3TC failure, a diﬀerence that4 ISRN Gastroenterology
was not statistically signiﬁcant [42]. Similarly, in another
retrospective study of 52 mostly 3TC-experienced patients
who subsequently received TDF, all 9 patients with virologic
breakthroughwerereceivingTDFincombinationwitheither
3TC or FTC, whereas none of the 9 patients receiving TDF
alone experienced virologic breakthrough [43]. The authors
of these studies have concluded that they could not show
an advantage to combination therapy within the follow-up
period of their studies.
Our report and that of Jain et al. [26] therefore provide
some of the ﬁrst data to support the current guidelines and
expert recommendations for the use of two antiviral agents
with activity against HBV; in addition, the present study
demonstrates an advantage of combination therapy at longer
followup than was reported previously. Nevertheless, both
studiessuggest thatinitial combinationtherapy issuperior to
rescuetherapyforpersonswithHIV/HBVcoinfection.While
there are clearly methodological diﬀerences between these
studies, the similarity of the observations providesa basis for
further investigation.
A beneﬁt of initial combination therapy against HBV
also reinforces the need to assess the baseline HBV status
of the patient prior to starting antiviral therapy for HIV.
Inappropriate antiviral therapy that only includes one agent
active against HBV could lead to long-term consequences
regarding HBV suppression, which in turn could ultimately
aﬀect risk of liver-related mortality.
The current study has limitations due to its retrospec-
tive design. Data on previous length of 3TC therapy and
treatment interruptions was incomplete. Data on cirrhosis
and liver histology was also incomplete. Monitoring of HBV
DNAlevelsand serologic markers was at thediscretion ofthe
individualproviders,sotherewerediﬀerencesintheintensity
of surveillance of viral loads among the 31 patients. Also,
the study population was small, limiting its ability to detect
small diﬀerences. In spite of this limitation, the median
time to HBV virologic suppression was substantially and
signiﬁcantly shorter in the 3TC-na¨ ıve group. There was also
greater suppression of HBVDNAat 24 months in 3TC-na¨ ıve
patients, and the diﬀerence again was statistically signiﬁcant
despite the small study size.
Diﬀerences in baseline status are potential confounders
in retrospective studies. For example, it has been noted that
greater HBV DNA baseline levels may result in the detection
of greater HBV DNA decreases on therapy [22]. However,
this was unlikely to be a major factor in our study since
baseline HBV DNA levels were similar in both our 3TC-
na¨ ıve and -experienced groups. Similarly, another potential
confoundercouldhavebeen baseline CD4+cellcount.There
is evidence that improvement in CD4+ lymphocyte count
during ART is associated with improvement in the evolution
of HBV disease [44–46]. Indeed, HBV-speciﬁc CD4+ lym-
phocyte activity has been shown to be important for control
of HBV infection in those without HIV coinfection as well
[47–49]. However, in the current study, the mean CD4+ cell
count was higher in the 3TC-experienced group, suggesting
that the observed superiority ofcombination therapy against
HBV in the 3TC-na¨ ıve group was unlikely to be the result of
better immunologic status in that group.
Ad i ﬀerence in adherence to treatment is another
potential confounder in retrospective studies, and we did
not directly analyze provider documented adherence rates.
If the 3TC-experienced group included more persons with
nonadherence to their ART regimen, then 3TC failure due
to nonadherence may increase TDF/FTC failure due to
nonadherence to TDF/FTC as well and bias the results
against the 3TC-exprienced group. However, adherence may
be inferred by assessing control of HIV viremia; since HIV
viremia onARTdidnotdiﬀerbetweenthegroups,we believe
that any diﬀerences in adherence would have had, at most, a
limited eﬀect on the results.
In summary, our ﬁndings show that patients who are
initially started on dual therapy with tenofovir and emtrici-
tabine have a shorter median time to suppression of HBV
DNA than those who are treated with tenofovir and emtric-
itabine after prior treatment with lamivudine; this obser-
vation suggests a beneﬁt from initially treating all persons
with HIV/HBV coinfection with ART containing two agents
with activity against HBV. Our ﬁndings therefore support
the current practice of starting dual therapy for hepatitis B
inHIV-/HBV-coinfectedpatients.Furtherstudiesare needed
to understand the clinical consequence of this, and whether
time to suppressionwill result in improvedclinical outcomes
regarding liver-related mortality. In addition to providing
evidence to support current treatment recommendations for
HIV/HBV coinfection, we speculate that such studies may
also eventually warrant investigation of potential beneﬁt for
those with HBV monoinfection.
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